Form 4: NeuroOne Medical Technologies General Counsel Granted Significant Stock Options

Emily J. Johns, General Counsel of NeuroOne Medical Technologies Corp., has been granted options to purchase 500,000 shares of common stock at an exercise price of $0.611 per share.

Summary

• Emily J. Johns, the General Counsel of NEUROONE MEDICAL TECHNOLOGIES Corp. (NMTC), was granted an option to purchase 500,000 shares of common stock.
• The exercise price for these options is $0.611 per share.
• The transaction date for this grant was June 1, 2025.
• The options become exercisable starting June 1, 2025, with an expiration date of May 31, 2035.
• The vesting schedule for these options is as follows: 25% will vest on June 1, 2026, and the remaining 75% will vest in 12 equal quarterly installments beginning on June 30, 2026.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of options aligns management incentives with shareholder interests, indicating confidence in future growth, though it's a routine compensation event.

Positives

• The grant of stock options to a key executive like the General Counsel aligns her interests with those of the shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period, providing a long window for the company's stock price to appreciate, potentially increasing the value of the compensation.

Negatives

• The potential future exercise of these 500,000 options could lead to dilution for existing shareholders, although this is a common aspect of equity compensation plans.

Risks

• The value of the granted options is directly tied to the future performance of NeuroOne Medical Technologies Corp.'s stock; if the stock price does not rise above the exercise price of $0.611, the options may not hold significant value.
• Market volatility and company-specific operational challenges could negatively impact the stock price, reducing the potential benefit of these options.

Future Outlook

The grant of these long-term stock options suggests an expectation of future growth and value creation for NeuroOne Medical Technologies Corp., as the options' value is contingent on the stock price appreciating above the exercise price over the next decade.

Management Comments

• The filing indicates that the transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

The granting of stock options to key executives is a standard practice across various industries, including the medical technology sector, to attract, retain, and incentivize talent by aligning their financial interests with the long-term success and shareholder value creation of the company.

Comparison to Industry Standards

• The use of stock options as a form of executive compensation is a common practice in the medical technology and broader biotech industries, similar to companies like Medtronic or Boston Scientific, though the specific grant size and exercise price are company-specific.
• The vesting schedule, with an initial cliff and subsequent quarterly installments, is a typical structure designed to encourage long-term commitment and performance from executives, consistent with industry benchmarks for executive equity grants.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from aligned management incentives for long-term stock appreciation.
• Employees (specifically Emily J. Johns): Receives significant equity compensation, incentivizing her to contribute to the company's success.

Next Steps

• The options will begin to vest on June 1, 2026, with subsequent quarterly vesting installments.
• The General Counsel may choose to exercise these options at any time after vesting and before the expiration date of May 31, 2035, assuming the stock price is favorable.

Key Dates

Recommendation

Keywords

NeuroOne Medical Technologies, NMTC, Stock Options, Executive Compensation, SEC Form 4, Insider Transaction, General Counsel, Equity Grant